Inari Medical Overview
Valuation check: NARI's ROE is -18.08%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-18.08%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Inari Medical (NARI) currently reports a ROE of -18.08%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Inari Medical's ROE history and peer comparisons.
Inari Medical's ROE of -18.08% is higher than the Healthcare sector average of -100.59%. That is roughly 82.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Inari Medical's current -18.08% should be judged against Healthcare norms (sector average: -100.59%) and against NARI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -18.08%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Inari Medical, and consider following NARI for alerts when major investors trade the stock.
Inari Medical is classified in the Healthcare sector. On ROE, it currently shows -18.08% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NARI with unrelated industries.
